RXRX250103P11500
- 0.00
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Cathie Wood's ARK Innovation ETF Couldn't Keep Up in 2024
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 30% Share Price Surge Not Quite Adding Up
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Express News | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Express News | Recursion Pharmaceuticals Inc - Registering for Resale 3.5 Mln Shares of Class a Common Stock
Express News | Recursion Pharmaceuticals Inc - Files Prospectus Supplement
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating